| Indicators | Browse All

LENSAR, Inc. (LNSR)

Healthcare | Medical Devices | Orlando, United States | NasdaqCM
8.30 USD -0.16 (-1.891%) ⇩ (Aug. 28, 2026, 4 p.m. EDT)
After hours: 8.36 +0.06 (0.723%) ⇧ (Aug. 28, 2026, 4:39 p.m. EDT)

Short-term:★★★⯪☆Long-term:★★⯪☆☆Dividends:☆☆☆☆☆
Hot Take | Aug. 22, 2026, 3:16 a.m. EDT

The investment case for LENSAR is currently paralyzed by the collapse of the Alcon acquisition. While the company boasts impressive operational metrics—nearly 58% profit margins and robust revenue growth—the stock has been punished severely by the market's reaction to the deal failure. The recent price action shows a tentative recovery from lows near $5, yet the path forward remains obscured by regulatory hurdles and the absence of a definitive strategic partner. For the short term, the setup is cautiously optimistic but fragile. The stock is trading well above its 200-day average, suggesting some buyers are stepping in at these levels, but the statistical forecast model offers almost no directional guidance, highlighting the noise inherent in this situation. The options market confirms this tension, with traders betting on a 'reset' scenario rather than a steady climb. Long-term, the business fundamentals are actually quite strong, with a fortress-like balance sheet and high profitability. However, the lack of a clear growth catalyst post-Alcon prevents a higher valuation multiple. Until the company can demonstrate a new, sustainable growth engine or secure a new major partnership, the risk of another disappointment outweighs the potential for immediate capital appreciation. Investors should wait for clarity on the next strategic chapter before committing significant capital.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.138417
MSTL0.140059
AutoETS0.147839
AutoARIMA0.147899

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 30%
H-stat 26.83
Ljung-Box p 0.000
Jarque-Bera p 0.031
Excess Kurtosis -0.84
Attribute Value
Sector Healthcare
Debt to Equity Ratio 8.299
Revenue per Share 4.962
Market Cap 101,972,680
Trailing P/E 41.50
Forward P/E -11.69
Beta 0.88
Profit Margins 57.57%
Website https://www.lensar.com

As of Aug. 22, 2026, 3:16 a.m. EDT: Speculators are positioning for a binary resolution to the failed Alcon merger. Call volume is heavily skewed toward out-of-the-money strikes at $10, suggesting a hope for a deal reset or a significant recovery rally. Conversely, put volume is concentrated at the $5 strike, indicating a fear of further downside if the regulatory impasse persists. Implied volatility remains elevated relative to deep OTM strikes, reflecting uncertainty rather than a clear directional bet.


Info Dump

Attribute Value
52 Week Change -0.31497973
Address1 2,800 Discovery Drive
All Time High 17.31
All Time Low 1.8
Ask 10.62
Ask Size 2
Audit Risk 8
Average Analyst Rating 1.0 - Strong Buy
Average Daily Volume10 Day 147,220
Average Daily Volume3 Month 119,337
Average Volume 119,337
Average Volume10Days 147,220
Beta 0.88
Bid 8.27
Bid Size 1
Board Risk 6
Book Value 1.214
City Orlando
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 9
Country United States
Crypto Tradeable 0
Currency USD
Current Price 8.3
Current Ratio 2.394
Custom Price Alert Confidence HIGH
Date Short Interest 1,786,665,600
Day High 8.52
Day Low 8.23
Debt To Equity 8.299
Display Name LENSAR
Earnings Call Timestamp End 1,786,624,200
Earnings Call Timestamp Start 1,786,624,200
Earnings Timestamp 1,786,624,200
Earnings Timestamp End 1,794,486,600
Earnings Timestamp Start 1,794,486,600
Ebitda -16,328,000
Ebitda Margins -0.27094
Enterprise To Ebitda -6.405
Enterprise To Revenue 1.735
Enterprise Value 104,572,680
Eps Current Year -0.08
Eps Forward -0.71
Eps Trailing Twelve Months 0.2
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 6.3881
Fifty Day Average Change 1.9119
Fifty Day Average Change Percent 0.29929087
Fifty Two Week Change Percent -31.497972
Fifty Two Week High 12.94
Fifty Two Week High Change -4.6399994
Fifty Two Week High Change Percent -0.35857803
Fifty Two Week Low 4.95
Fifty Two Week Low Change 3.3500004
Fifty Two Week Low Change Percent 0.67676777
Fifty Two Week Range 4.95 - 12.94
Financial Currency USD
First Trade Date Milliseconds 1,601,645,400,000
Float Shares 8,842,506
Forward Eps -0.71
Forward P E -11.690142
Free Cashflow -24,391,250
Full Exchange Name NasdaqCM
Full Time Employees 150
Fullday Change -0.16
Fullday Change Percent -1.89125
Fullday Price 8.36
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,785,542,400
Gross Margins 0.48339
Gross Profits 29,131,000
Has Pre Post Market Data 1
Held Percent Insiders 0.21521999
Held Percent Institutions 0.45979
Implied Shares Outstanding 12,285,865
Industry Medical Devices
Industry Disp Medical Devices
Industry Key medical-devices
Is Earnings Date Estimate 0
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
Long Name LENSAR, Inc.
Market us_market
Market Cap 101,972,680
Market State CLOSED
Max Age 86,400
Message Board Id finmb_41699596
Most Recent Quarter 1,782,777,600
Net Income To Common 14,700,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 104,061,276
Number Of Analyst Opinions 2
Open 8.43
Operating Cashflow -7,293,000
Operating Margins 0.12937
Overall Risk 8
Payout Ratio 0.0
Phone 888 536 7271
Post Market Change 0.059999466
Post Market Change Percent 0.72288513
Post Market Price 8.36
Post Market Time 1,787,949,541
Previous Close 8.46
Price Eps Current Year -103.75001
Price Hint 2
Price To Book 6.836903
Price To Sales Trailing12 Months 1.6920995
Profit Margins 0.57573
Quick Ratio 1.03
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.0
Region US
Regular Market Change -0.16
Regular Market Change Percent -1.89125
Regular Market Day High 8.52
Regular Market Day Low 8.23
Regular Market Day Range 8.23 - 8.52
Regular Market Open 8.43
Regular Market Previous Close 8.46
Regular Market Price 8.3
Regular Market Time 1,787,947,201
Regular Market Volume 142,330
Return On Assets -0.18663
Return On Equity 3.5730398
Revenue Growth 0.184
Revenue Per Share 4.962
Sand P52 Week Change 0.20504117
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 9
Shares Outstanding 12,285,865
Shares Percent Shares Out 0.033800002
Shares Short 415,434
Shares Short Previous Month Date 1,784,073,600
Shares Short Prior Month 483,171
Short Name LENSAR, Inc.
Short Percent Of Float 0.0468
Short Ratio 2.89
Source Interval 15
State FL
Symbol LNSR
Target High Price 13.0
Target Low Price 10.0
Target Mean Price 11.5
Target Median Price 11.5
Total Cash 13,565,000
Total Cash Per Share 1.104
Total Debt 2,381,000
Total Revenue 60,264,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 0.2
Trailing P E 41.5
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 8.389575
Two Hundred Day Average Change -0.089574814
Two Hundred Day Average Change Percent -0.0106769195
Type Disp Equity
Volume 142,330
Website https://www.lensar.com
Zip 32,826